Axon Enterprise, Inc. (NASDAQ:AXON) Given Consensus Rating of “Buy” by Brokerages

Axon Enterprise, Inc. (NASDAQ:AXON) has received an average recommendation of “Buy” from the fourteen ratings firms that are covering the company, MarketBeat reports. Fourteen equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $542.15.

Several research firms have weighed in on AXON. Robert W. Baird lifted their target price on Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a research report on Friday, December 6th. JMP Securities lifted their price objective on Axon Enterprise from $610.00 to $725.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 4th. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $500.00 to $700.00 in a research note on Tuesday, December 3rd. TD Cowen started coverage on Axon Enterprise in a research note on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price objective for the company. Finally, The Goldman Sachs Group lifted their price objective on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research note on Monday, January 27th.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $710.01 on Wednesday. The company has a market cap of $54.14 billion, a P/E ratio of 183.47, a P/E/G ratio of 6.79 and a beta of 1.05. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a 50-day moving average of $625.48 and a two-hundred day moving average of $514.81. Axon Enterprise has a 1-year low of $260.27 and a 1-year high of $715.99.

Insider Buying and Selling

In other Axon Enterprise news, Director Julie A. Cullivan sold 1,261 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $682.06, for a total transaction of $860,077.66. Following the transaction, the director now owns 2,392 shares of the company’s stock, valued at $1,631,487.52. The trade was a 34.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the transaction, the director now directly owns 6,929 shares in the company, valued at approximately $4,185,601.03. This trade represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,711 shares of company stock worth $5,631,561 over the last 90 days. 6.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Capital World Investors increased its holdings in shares of Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock valued at $1,079,145,000 after purchasing an additional 841,772 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Axon Enterprise by 273.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock valued at $659,128,000 after purchasing an additional 812,337 shares during the period. Norges Bank acquired a new position in shares of Axon Enterprise in the fourth quarter valued at approximately $482,081,000. GQG Partners LLC acquired a new position in shares of Axon Enterprise in the fourth quarter valued at approximately $478,349,000. Finally, Groupama Asset Managment acquired a new position in shares of Axon Enterprise in the third quarter valued at approximately $200,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.